MedTrace Logo

European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up

NCT04017325 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 374

Last updated 2021-03-22

No results posted yet for this study

Summary

This is an open observational extended follow-up study of patients originally randomized into TOOKAD® Soluble VTP therapy or active surveillance (control group). Additional 60-month follow-up study

Conditions

  • Cancer of the Prostate

Interventions

OTHER

no intervention (post study follow up)

No intervention (post study follow up)

Sponsors & Collaborators

  • International Drug Development Institute

    collaborator OTHER

  • ICON plc

    collaborator INDUSTRY

  • Steba Biotech S.A.

    lead OTHER

Principal Investigators

  • Mark EMBERTON, Professor · University College of London Hospital , United Kingdom

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-17
Primary Completion
2020-06-03
Completion
2020-06-03

Countries

  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04017325 on ClinicalTrials.gov